Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Addition of Ezetimibe (Ezetrol®) to Ongoing Therapy With Rosuvastatin (Crestor®) in HIV Positive Patients Not Reaching Cholesterol Targets

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2011 by University of British Columbia.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Merck Frosst-Schering Pharma, G.P.
Information provided by (Responsible Party):
University of British Columbia
ClinicalTrials.gov Identifier:
NCT00908011
First received: May 21, 2009
Last updated: November 21, 2011
Last verified: November 2011

May 21, 2009
November 21, 2011
June 2009
Not Provided
The primary endpoint is the difference in final value of serum apolipoprotein B between participants treated with rosuvastatin versus participants treated with both rosuvastatin and ezetimibe. [ Time Frame: 3 months from baseline ] [ Designated as safety issue: No ]
Apolipoprotein B100/apolipoprotein A1 ratio [ Time Frame: 3 months from baseline ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00908011 on ClinicalTrials.gov Archive Site
  • Percent change in apolipoprotein B, percent and absolute change total cholesterol, LDL, HDL, triglycerides, apolipoprotein A1, apolipoproteinB/apoliporoteinA1 ratio and C-reactive protein [ Time Frame: 3 months from baseline ] [ Designated as safety issue: No ]
  • Assessment of safety parameters, specifically incidence of complications as measured by an increase in AST &/or ALT ≥3-fold ULN & a CK ≥10-fold ULN [ Designated as safety issue: Yes ]
Improvement in serum lipid parameters, namely total cholesterol, LDL, HDL, triglycerides and apolipoprotein B100, apolipoprotein A1 [ Time Frame: 3 months from baseline ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Addition of Ezetimibe (Ezetrol®) to Ongoing Therapy With Rosuvastatin (Crestor®) in HIV Positive Patients Not Reaching Cholesterol Targets
A Prospective, Randomized Study to Determine the Effect of Ezetimibe in Addition to Rosuvastatin on Lipids in Participants With the Hypercholesterolemia Associated With HIV Antiretroviral Therapy

This study involves comparing the effectiveness of treatments in HIV positive patients who may be predisposed to heart attack or stroke. The investigators will evaluate the effectiveness of two drugs, often prescribed by doctors to these patients, at lowering cholesterol and thereby making the patient less them less vulnerable to suffering a heart attack or stroke. The investigators believe that the addition of a second drug, from a different class of cholesterol lowering medications, will improve the outcome of the patients by lowering cholesterol.

This study seeks to determine whether HIV positive patients who have suboptimal lipids and/or are not reaching specified lipid targets will benefit from the addition of a second lipid lowering drug (ezetimibe) to existing lipid lowering therapy with a statin (specifically rosuvastatin) versus increasing the dose of the ongoing statin in terms of improvements in serum lipid parameters namely total cholesterol, LDL, HDL, triglycerides and apolipoprotein B100 (apoB), apolipoprotein A1 (apoA1), apoB/apoA1 ratio.

The target population will be HIV+ patients with hypercholesterolemia due to highly active antiretroviral therapy, the study will have a randomized, parallel design. Sample size will be 50 patients already taking 10 mg of rosuvastatin who are not reaching lipid targets to receive either an increased dose of rosuvastatin (20mg) or to receive 10mg ezetimibe in addition to their ongoing rosuvastatin therapy. There will be 25 patients randomized to each group.

At baseline serum samples will be obtained and tested for serum triglycerides, total cholesterol, HDL, total cholesterol:HDL ratio, apoB, apoA1, apoB/apoA1 ratio, liver transaminases (AST and ALT), CK, thyroid stimulating hormone, creatinine and fasting blood glucose.

After 12 weeks of therapy serum samples will once again be obtained and tested for serum triglycerides, total cholesterol, HDL, total cholesterol:HDL ratio, apolipoprotein B100, liver transaminases (AST and ALT), CK, thyroid stimulating hormone, creatinine and fasting blood glucose.

The primary hypothesis is that the combination of rosuvastatin and ezetimibe will lower serum apolipoprotein B100/apolipoprotein A1 ratio more so than an increased dose of rosuvastatin alone, in participants with mixed dyslipidemia associated with HIV therapy.

Secondarily we believe the combination of rosuvastatin and ezetimibe will lower the concentrations of serum cholesterol, LDL-cholesterol, triglycerides, apolipoprotein B100 and C-reactive protein more so than an increased dose of rosuvastatin alone, and that there will be no increase in side effects when administered to participants with mixed dyslipidemia associated with HIV therapy.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Hypercholesterolemia
  • HIV Infections
  • Drug: Ezetimibe
    10mg/day ezetimibe in addition to ongoing rosuvastatin treatment (10mg/day)- tablet, orally, 10mg/day for 12 weeks
    Other Name: Ezetrol
  • Drug: Rosuvastatin (standard care)
    Increased dose of rosuvastatin to 20mg/day
    Other Name: Crestor
  • Active Comparator: Ezetimibe
    10mg/day ezetimibe in addition to ongoing rosuvastatin treatment (10mg/day)
    Intervention: Drug: Ezetimibe
  • Active Comparator: Standard Care
    Increased dose of rosuvastatin to 20mg/day
    Intervention: Drug: Rosuvastatin (standard care)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
50
Not Provided
Not Provided

Inclusion Criteria:

  • HIV positive
  • currently taking 10mg of rosuvastatin
  • recent (within three months) fasting lipid profile in which the serum total cholesterol to HDL ratio is >5.0

Exclusion Criteria:

  • Previous adverse reaction to ezetimibe
  • taken ezetimibe within 30 days of starting the study
  • history of vascular disease
  • allergic reaction or muscle problems while taking any statin
  • currently taking other lipid lowering medications (i.e. a fibrates or cholestyramine)
Both
19 Years and older
No
Contact: Kevin Johns (604) 682-2344 ext 63139 kevinwjohns@gmail.com
Canada
 
NCT00908011
H08-00287
No
University of British Columbia
University of British Columbia
Merck Frosst-Schering Pharma, G.P.
Principal Investigator: Greg Bondy, MD University of British Columbia
University of British Columbia
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP